MSK Ventures

Advancing Cancer Innovation Through Strategic Investment

Memorial Sloan Kettering Cancer Center is proud to announce the formation of MSK Ventures, a dedicated venture capital fund launching in 2026. MSK Ventures is designed to invest in high-conviction companies with an affiliation or mission alignment with MSK—alongside credible investors and dedicated leadership teams—providing structured capital to help these companies achieve critical value inflection points. The fund will enable MSK to systematically invest in and help develop, scale, and, in some instances, translate new discoveries and services while diversifying long-term revenue streams. 

Our Mission

With a mission-aligned dual mandate deeply embedded in MSK’s 2030 vision, MSK Ventures will both advance patient-impactful innovation coming from or integral to MSK and generate institutional-quality financial returns for MSK and its limited partners.

MSK Ventures is a key program within the MSK Commercialization Ecosystem, with executive leadership from Anaeze Offodile II, MD, MPH, MSK’s Executive Vice President and Chief Strategy Officer. Whitney Snider, MD, MBA, has joined MSK as MSK Ventures’ leader, serving as Inaugural Managing Partner. 

MSK Ventures will work synergistically with another key program in the Commercialization Ecosystem, the Office of Entrepreneurship & Commercialization (OEC), led by Yashodhara Dash, MBBS, PhD, MBA. Alongside OEC programs such as Therapeutics Bridge Lab and the Entrepreneurship Initiative, MSK Ventures will help cultivate a durable culture of innovation—one that attracts and empowers top scientific talent, accelerates the translation of bold ideas into companies, and ensures that breakthrough science reaches patients while strengthening MSK’s financial foundation for decades to come.

MSK Ventures and the OEC are designed to empower and accelerate entrepreneurship and innovation at MSK at different stages of development and maturity.  MSK Ventures will have access to investment opportunities among promising projects being incubated through MSK’s Entrepreneurship Initiative, Technology Development Investment Fund, and other OEC initiatives, as well as existing companies with MSK affiliation or key strategic alignment.

Leadership

Whitney Snider, MD, MBA, Inaugural Managing Partner

Dr. Snider brings exceptional expertise at the intersection of science, entrepreneurship, and strategic investing to lead MSK Ventures through its formation and launch phases.

Dr. Snider joined MSK in 2026, after having served as Principle and Vice President of Life Sciences at Alexandria Venture Investments. For more about Dr. Snider, see here.

Whitney Snider

Strategic Vision

MSK Ventures represents a bold commitment to shaping the future of cancer innovation. We are investing in high-conviction companies rooted in MSK’s science, intellectual property, and collaborative ecosystem—spanning AI, therapeutics, and platform technologies—with the goal of accelerating breakthroughs that meaningfully impact patients. By pairing structured capital with world-class partners and leadership teams, we aim to help companies reach critical inflection points while generating enduring value that strengthens MSK’s mission for decades to come.
Whitney Snider, MD, MBA
Managing Partner, MSK Ventures
We are very excited to welcome Dr. Snider to MSK. She brings exceptional judgment, a powerful professional network, and a distinguished track record in strategic biotechnology investing. Together, these strengths will accelerate the activation and expansion of the MSK Ventures portfolio, positioning it for transformative impact. We view MSK Ventures as a pivotal lever in advancing the institution's long-term innovation and growth ambitions.
Anaeze Offodile II, MD, MPH
Executive Vice President and Chief Strategy Officer, MSK

Fund Status

MSK Ventures is currently in formation. 

The fund launched in 2026 and will continue its rollout through 2026 as it builds out its investment platform and portfolio.

For more information about MSK Ventures, please contact [email protected]. 

News & Events

Whitney Snider, MD, MBA Joins MSKCC as Inaugural Managing Partner of MSK Ventures

MSK Ventures represents Memorial Sloan Kettering's commitment to transforming cancer care through strategic investment in breakthrough innovations that emerge from our world-class research and clinical enterprise.

Read more

Q&A Interview with Dr. Whitney Snider

Dr. Snider spoke with our team about her plans, priorities, and early impressions. Read here